Implementing HUGO™ RAS for Radical Prostatectomy– a retrospective monocentric comparison to the da Vinci Xi® system
This retrospective monocentric study demonstrates that the HUGO™ RAS system achieves early perioperative and pathological outcomes comparable to the da Vinci Xi® platform for robot-assisted radical prostatectomy after adjusting for confounders, despite a non-significant trend toward longer operative times.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Prostate cancer, a disease that affects the male reproductive system, is often treated by surgically removing the entire prostate gland. For decades, this operation was performed through large incisions, but a major shift occurred with the arrival of robotic surgery. In this approach, a surgeon sits at a console and controls robotic arms that hold tiny instruments, allowing for extreme precision inside the body through very small cuts. For over twenty years, one specific robotic system, known as the da Vinci, has been the dominant tool used in hospitals around the world. However, as patents on the original technology expired, new competitors have entered the field. One of these newcomers is a system called HUGO. The medical community is eager to know if this new machine can perform the complex task of removing a prostate just as safely and effectively as the established leader, or if the older system remains superior.
A team of researchers at a university hospital in Germany set out to answer this question by looking back at their own recent work. They compared two groups of patients who underwent the same type of prostate removal surgery between April 2024 and December 2025. One group of fifty patients was treated using the new HUGO robot, while a slightly larger group of fifty-seven patients was treated using the established da Vinci system. Crucially, both groups were operated on by the same two experienced surgeons, who used both machines during the study period. This setup helped ensure that differences in the results were due to the machines themselves rather than the skill of the doctors. The researchers carefully examined the time the surgery took, how long patients stayed in the hospital, whether the cancer was completely removed, and if there were any complications.
The initial look at the data showed a small difference in how long the surgeries took. The operations using the HUGO robot took about twenty-one minutes longer on average than those using the da Vinci system. However, when the researchers adjusted for the fact that the patients in the HUGO group had slightly more complex cancer cases and higher health risks, this time difference disappeared statistically. In other words, the extra time was likely due to the learning curve of using a new machine and the specific challenges of the patients, not a fundamental flaw in the robot's ability to work. Beyond the operating room, the two groups performed almost identically. The length of hospital stays was the same, and the rate of complications was low and equal for both. The surgeons were equally successful at removing the cancer completely, as measured by the edges of the removed tissue, and they retrieved the same number of lymph nodes to check for cancer spread.
One interesting detail emerged regarding the preservation of nerves that control erections. The surgeons planned to save these nerves less often for the HUGO group, likely because they were still getting comfortable with the new system and chose to be more cautious with complex cases. However, when they did plan to save the nerves, they succeeded in doing so for every single patient in the HUGO group, a rate that was actually higher than what they achieved with the older system for similar cases. After accounting for these differences in planning, the final outcome for nerve preservation was statistically the same for both machines. The study also noted that while the new robot worked well, it did experience a couple of technical hiccups, such as a robotic arm malfunction and a docking failure that required a switch to open surgery, though these were rare events.
The researchers concluded that the new HUGO robot is a viable and safe alternative to the long-standing da Vinci system for removing the prostate. The early results suggest that the new machine can achieve the same high standards of care regarding cancer removal and patient recovery. While the new system took slightly longer to set up and use during this initial phase, the difference was not significant enough to affect the patient's outcome. The study emphasizes that the skill of the surgeon and the specific needs of the patient matter more than the brand of robot used. To fully confirm these findings and understand how the new robot affects long-term recovery and cancer control, larger studies with more patients and longer follow-up periods are needed, but the initial evidence is promising.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.